Peptide Therapy for Musculoskeletal Injuries: Safety & Efficacy Review (2026)

A landmark narrative review published in *Sports Medicine* (April 2026) offers the most comprehensive, peer-reviewed framework to date for evaluating both approved and unapproved peptides in the context of injury recovery and athletic performance. For patients and clinicians navigating the rapidly expanding peptide landscape, this study provides critical context — separating compounds with established regulatory track records from those operating in a largely unregulated gray market.

**Citation:** Mendias CL, Awan TM. *Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.* Sports Medicine. 2026 Apr 12. doi: 10.1007/s40279-026-02437-0. PMID: 41966639.

Conducted by researchers at the Performance Medicine Institute in Phoenix, Arizona, this narrative review evaluated the pharmacological mechanisms, safety profiles, and regulatory status of twelve prominent peptides currently marketed — often directly to consumers — for musculoskeletal healing and performance enhancement. The compounds reviewed include:

The authors also address the placebo effect as a meaningful mediator of perceived peptide efficacy, and how social media actively amplifies patient expectations around these compounds.

This review matters because it arrives at a moment when peptide inquiries in sports medicine and longevity practices have surged dramatically. Patients are arriving to consultations having already self-researched — and in many cases self-administered — compounds they sourced online. The authors bring academic rigor to a space that has historically been shaped more by anecdote and influencer content than peer-reviewed evidence.

Critically, the study does not dismiss unapproved peptides categorically. Instead, it calls for proportional skepticism: acknowledging the biological plausibility of mechanisms seen in animal studies while being transparent that human efficacy and safety data are either early-stage or entirely absent for most gray-market compounds.

If you are considering peptide therapy for a musculoskeletal injury, tendon repair, or performance optimization, this study reinforces several principles I apply in my own practice:

The authors acknowledge several limitations inherent to this work: